Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals

Hakariya, Hayase; Moriarty, Frank; Ozaki, Akihiko; Mulinari, Shai; Saito, Hiroaki; Tanimoto, Tetsuya

dc.contributor.author	Hakariya, Hayase
dc.date.accessioned	2024-12-02T09:15:31Z
dc.date.available	2024-12-02T09:15:31Z
dc.date.issued	2024
dc.identifier.issn	1752-8054
dc.identifier.uri	http://hdl.handle.net/10900/159229
dc.language.iso	en	de_DE
dc.publisher	Hoboken : Wiley	de_DE
dc.relation.uri	http://dx.doi.org/10.1111/cts.13879	de_DE
dc.subject.ddc	610	de_DE
dc.title	Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals	de_DE
dc.type	Article	de_DE
utue.quellen.id	20241001000000_00906
utue.personen.roh	Hakariya, Hayase
utue.personen.roh	Moriarty, Frank
utue.personen.roh	Ozaki, Akihiko
utue.personen.roh	Mulinari, Shai
utue.personen.roh	Saito, Hiroaki
utue.personen.roh	Tanimoto, Tetsuya
dcterms.isPartOf.ZSTitelID	Cts - Clinical and Translational Science	de_DE
dcterms.isPartOf.ZS-Issue	Article e13879	de_DE
dcterms.isPartOf.ZS-Volume	17 (7)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE